Skip to main
CNMD
CNMD logo

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp demonstrated strong performance with General Surgery sales growing by 8.7% to $206.9 million, exceeding consensus estimates, while Orthopedic Surgery sales also surpassed expectations at $139.0 million, representing a 2.4% increase. The Company achieved an operating margin of 18.6%, up 280 basis points year-over-year, driven by gross margin expansion and effective operating leverage, positioning Conmed for future margin improvement. Furthermore, the gross margin reached 57.6%, slightly above expectations, indicating robust financial health despite ongoing supply chain challenges.

Bears say

Conmed Corp's financial outlook is negatively impacted by a projected slowdown in revenue growth, which is expected to fall to 4% or less due to lower-than-expected sales from key products such as AirSeal and Buffalo Filter, as well as challenges with new product launches. Additionally, management's guidance for 2025 revenue and earnings per share (EPS) is below consensus, indicating ongoing supply chain issues and potential pressure on operating margins. The company has also revised its revenue estimates downward for 2025 and 2026, reflecting a cautious stance amid risks related to hospital capital spending and adverse currency fluctuations.

CONMED (CNMD) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Buy based on their latest research and market trends.

According to 14 analysts, CONMED (CNMD) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.